We are a fast-growing, international biotech company committed to improving the lives of people with our differentiated antibody medicines.
We have committed to a new vision for our future that by 2030, our knock-your-socks-off (KYSO®) antibodies are fundamentally transforming the lives of people with cancer and other serious diseases.
| ||||||||
| ||||||||
We have a proven track record in discovery and development, which we are now augmenting with commercial capabilities as we transition into an integrated biotech with the aspiration to bring medicines to patients.
Founded in Copenhagen, Denmark in 1999, Genmab A/S’s ordinary shares are listed on the Nasdaq Copenhagen A/S under the ticker symbol GMAB and are traded as part of the OMXC25. Genmab’s American Depositary Shares issued under the ADR Program are listed in the U.S. on the Nasdaq Global Select Market under the ticker symbol GMAB, and the shares are included in the NASDAQ Biotechnology Index (Nasdaq: NBI).
Search and read Genmab’s most recent and previous financial reports.
See our statements, reports, and other forms submitted to the U.S. Securities and Exchange Commission (SEC).
We are committed to being a sustainable and socially responsible biotech company.
Our passion for innovation is driven by data and rooted in science.
See the results of our innovation that is driven by data.
Our commitment to corporate governance is based on ethics and integrity.
Our aim is to deliver reliable and transparent information to our shareholders. If you have questions about Genmab, our products or other relevant shareholder information, please use the information below to contact us. We will handle your personal data in accordance with our Privacy Policy.
Vice President,
Head of Investor Relations
Telephone: +45 3377 9558
Email: [email protected]
Carl Jacobsens Vej 30
2500 Valby
Denmark
For general Investor Relations Inquiries please contact [email protected].
See snapshots of our balance sheets,
cash flow and other statements
Access our financial reports, webcasts, presentations and more
Sign up to receive email alerts with
our latest news